Some 22 leading figures from the UK's biotechnology industry, including high-profile names such as sector investor Sir Christopher Evans and Nomura Code Securities chief executive Chris Collins, have presented the government with a 22-page dossier which identifies the need for "seismic" change to save and transform the situation for these firms, calling for a rescue package of L500.0 million ($742.3 million) from the state.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze